Amit Kumar Tripathi, PhD of the Vishwanatha research lab recently had an article published in the reputed Journal of Biological Chemistry. The groundbreaking study focused on first-in-class peptide molecules designed to target specific MIEN1 cancer signaling pathways for which no inhibitors have been identified thus far. The newly identified peptides exhibit selective cytotoxicity against breast cancer cells in a mouse model while demonstrating non-toxicity to normal cells and possessing a favorable pharmacokinetic profile. The findings present a novel approach to understanding and potentially intervening in this crucial signaling pathway, offering new perspectives on cancer treatment.
Read his article here: Tripathi et al.